Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancer—A Single Institution Experience


Chemotherapy with continuous infusion of 5-fluorouracil and cisplatin in a monthly schedule is one of the most common regimens in the treatment of advanced gastric cancer. In this study, we evaluated the efficacy and safety of a dosedense administration of this regimen in this patient population. Sixty-six consecutive patients with previously untreated histologically confirmed unresectable or metastatic gastric adenocarcinoma were treated with a 2-hour infusion of cisplatin 100 mg/m2 followed by continuous infusion of 5-fluorouracil 1000 mg/m2/day for 5 days, every 21 days. The most common grade ≥3 toxicities were fatigue (42%), nausea/vomiting (30%) and leucopenia (12%). Four patients (6%) died from treatment-related toxicity. The response rate was 35%, the median progression-free survival was 4.3 months and the median survival was 5.9 months. In light of these results, the dose-dense approach seems to offer little, if any, benefit compared with the standard regimens.

Share and Cite:

O. Purim, Y. Kundel, R. Shapira and B. Brenner, "Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancer—A Single Institution Experience," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 529-535. doi: 10.4236/jct.2013.42066.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] J. T. Diehl, R. E. Hermann, A. M. Cooperman and S. O. Hoerr, “Gastric Carcinoma: A Ten-Year Review,” Annals of Surgery, Vol. 198, No. 1, 1983, pp. 9-12. doi:10.1097/00000658-198307000-00003
[2] G. McNeer, H. Vandenberg, F. Y. Donn and L. Bowden, “A Critical Evaluation of Subtotal Gastrectomy for the Cure of Cancer of the Stomach,” Annals of Surgery, Vol. 134, No. 1, 1951, pp. 1-7. doi:10.1097/00000658-195107000-00002
[3] L. L. Gunderson and H. Sosin, “Adenocarcinoma of the Stomach: Areas of Failure in a Reoperation Series (Second or Symptomatic Look)—Clinicopathologic Correlation and Implications for Adjuvant Therapy,” International Journal of Radiation Oncology * Biology * Physics, Vol. 8, No. 1, 1982, pp. 1-11. doi:10.1016/0360-3016(82)90377-7
[4] J. B. Dupont Jr., J. R. Lee, G. R. Burton and I. Cohn, Jr., “Adenocarcioma of the Stomach: Review of 1497 Cases,” Cancer, Vol. 41, No. 3, 1978, pp. 941-947. doi:10.1002/1097-0142 (197803)41:3<941::AID-CNCR 2820410323>3.0.CO;2-M
[5] S. Pyrhonen, T. Kuitunen and M. Kouri, “A Randomized Phase III Trial Comparing Fluorouracil, Epidoxorubicin and Methotrexate (FEMTX) with Best Supportive Care in Non-Resectable Gastric Cancer,” Annals of Oncology, Vol. 3 Suppl 5, 1992.
[6] B. Glimelius, K. Ekstrom, K. Hoffman, W. Graf, P. O. Sjodén, U. Haglund, et al., “Randomized Comparison between Chemotherapy plus Best Supportive Care with Best Supportive Care in Advanced Gastric Cancer,” Annals of Oncology, Vol. 8, No. 2, 1997, pp. 163-168. doi:10.1023/A:10 08243606668
[7] A. M. Murad, F. F. Santiago, A. Petroianu, P. R. Rocha, M. A. Rodrigues and M. Rausch, “Modified Therapy with 5-Fluorouracil, Doxorubicin and Methotrexate in Advanced Gastric Cancer,” Cancer, Vol. 72, No. 1, 1993, pp. 37-41. doi:10.1002/1097-0142(19930701)72:1<37::AID-CNCR282072 0109>3.0.CO;2-P
[8] J. A. Akoh and I. M. C. Mcintyre, “Improving Survival in Gastric Cancer: Review of 5-Year Survival Rates in English Language Publications from 1970,” British Journal of Surgery, Vol. 79, No. 4, 1992, pp. 293-299. doi:10.1002/bjs.1800790404
[9] J. Wils, H. Klein, D. Wagener, H. Bleiberg, H. Reis, F. Korsten, et al., “Sequential High-Dose Methotrexate and Fluorouracil Combined with Doxorubicin: A Step Ahead in the Treatment of Advanced Gastric Cancer—A Trial of the EORTC Gastrointestinal Tract Cooperative Group,” Journal of Clinical Oncology, Vol. 9, No. 5, 1991, pp. 827-831.
[10] F. M. Schabel, M. W. Trader, W. R. Laster, T. H. Corbett and D. P. Griswold Jr., “Cis-Dichlorodiammineplatinum (II): Combination Chemotherapy and Cross-Resistance Studies with Tumors of Mice,” Cancer Treatment Reports, Vol. 63, No. 9-10, 1979, pp. 1459-1473.
[11] M. Rooney, J. Kish, J. Jacobs, J. Kinzie, A. Weaver, J. Crissman, et al., “Improved Complete Response Rate and Survival in Advanced Head and Neck Cancer after Three-Course Induction Therapy with 120-Hour 5-FU Infusion and Cisplatin,” Cancer, Vol. 55, No. 5, 1985, pp. 1123-1128. doi:10.1002/1097-0142(19850301)55:5<1123::AID-CNCR2820550530>3.0.CO;2-8
[12] K. J. Scanlon, E. M. Newman, Y. Lu and D. G. Priest, “Biochemical Basis for Cisplatin and 5-Fluorouracil Synergism in Human Ovarian Carcinoma Cells,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 83, No. 23, 1986, pp. 8923-8925. doi:10.1073/pnas.83.23.8923
[13] T. Shirasaka, Y. Shimamoto, H. Ohshima, H. Saito and M. Fukushima, “Metabolic Basis of the Synergistic Antitumor Models in Vivo,” Cancer Chemotherapy and Pharmacology, Vol. 32, No. 3, 1993, pp. 167-172. doi:10.1007/BF00685830
[14] J. J. Lokich, J. D. Ahlgren, J. J. Gullo, J. A. Phillips and J. G. Fryer, “A Prospective Randomized Comparison of Continuous Infusion Fluorouracil with a Conventional Bolus Schedule in Metastatic Colorectal Carcinoma: A Mid-Atlantic Oncology Program Study,” Journal of Clinical Oncology, Vol. 7, No. 4, 1989, pp. 425-432.
[15] T. Moynihan, R. Hansen, T. Anderson, E. Quebbeman, P. Beatty, R. Ausman, et al., “Continuous 5-Fluorouracil Infusion in Advanced Gastric Carcinoma,” American Journal of Clinical Oncology, Vol. 11, No. 4, 1988, pp. 461-464. doi:10.1097/00000421-198808000-00010
[16] J. A. Kish, J. F. Ensley, J. Jacobs, A. Weaver, G. Cummings and M. Al-Sarraf, “A Randomized Trial of Cisplatin + 5-FU Infusion and Cisplatin +5-FU Bolus for Recurrent and Advanced Squamous Cell Carcinoma of Head and Neck,” Cancer, Vol. 56, No. 12, 1985, pp. 2740-2744. doi:10.1002/1097-0142(19851215)56:12<2740::AID-CNCR2820561203>3.0.CO;2-Y
[17] R. M. Hansen, L. Ryan, T. Anderson, B. Krzywda, E. Quebbeman, A. Benson 3rd, et al., “Phase III Study of Bolus versus Infusion Fluorouracil with or without Cisplatin in Advanced Colorectal Cancer,” Journal of the National Cancer Institute, Vol. 88, No. 10, 1996, pp. 668-674. doi:10.1093/ jnci/88.10.668
[18] A. J. Lacave, F. J. Barón, L. M. Antón, E. Estrada, L. M. De Sande, I. Palacio, et al., “Combination Chemotherapy with Cisplatin and 5-Fluorouracil 5-Day Infusion in the Therapy of Advanced Gastric Cancer: A Phase II Trial,” Annals of Oncology, Vol. 2, No. 10, 1991, pp. 751-754.
[19] P. Rougier, M. Ducreux, M. Mahjoubi, J. P. Pignon, S. Bellefqih, J. Oliveira, et al., “Efficacy of Combined 5-Fluorouracil and Cisplatinum in Advanced Gastric Carcinomas: A Phase II Trial with Prognostic Factor Analysis,” European Journal of Cancer, Vol. 30, No. 9, 1994, pp. 1263-1269. doi:10.1016/0959-8049(94)90170-8
[20] S. Kummel, M. Rezai, R. Kimmig and P. Schmid, “DoseDense Chemotherapy for Primary Breast Cancer,” Current Opinion in Obstetrics and Gynecology, Vol. 19, No. 1, 2007, pp. 75-81. doi:10.1097/GCO.0b013e328011f99a
[21] L. Anderson-Reitz, “Dose-Dense Chemotherapy for Aggressive Non-Hodgkin Lymphoma,” Cancer Nursing, Vol. 29, No. 3, 2006, pp. 198-206. doi:10.1097/00002820-200605000-00005
[22] V. Diehl, J. Franklin, D. Hasenclever, H. Tesch, M. Pfreundschuh, B. Lathan, et al., “BEACOPP, a New Dose-Escalated and Accelerated Regimen, Is at Least as Effective as COPP/ABVD in Patients with Advanced-Stage Hodgkin’s Lymphoma: Interim Report from a Trial of the German Hodgkin’s Lymphoma Study Group,” Journal of Clinical Oncology, Vol. 16, No. 12, 1998, pp. 3810-3821.
[23] M. L. Citron, D. A. Berry, C. Cirrincione, C. Hudis, E. P. Winer, W. J. Gradishar, et al., “Randomized Trial of DoseDense versus Conventionally Scheduled and Sequential versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741,” Journal of Clinical Oncology, Vol. 21, No. 8, 2003, pp. 1431-1439. doi:10.1200/JCO.2003.09.081
[24] S. Cascinu, R. Labianca, P. Alessandroni, M. Marcellini, R. R. Silva, G. Pancera, et al., “Intensive Weekly Chemotherapy for Advanced Gastric Cancer Using Fluorouracil, Cisplatin, Epi-Doxorubicin, 6S-Leucovorin, Glutathione, and Filgrastim: A Report from the Italian Group for the Study of Digestive Tract Cancer,” Journal of Clinical Oncology, Vol. 15, No. 11, 1997, pp. 3313-3319.
[25] J. R. Jacobs, K. K. Fu, L. D. Lowry, Scotte R. L. Doggett, T. F. Pajak and M. Al-Sarraf, “5-Year Results of Cisplatin and Fluorouracil Infusion in Head and Neck Cancer,” Archives of Otolaryngology—Head and Neck Surgery, Vol. 117, No. 3, 1991, pp. 288-291. doi:10.1001/archotol.1991.01870150056006
[26] M. Al-Sarraf, K. Martz, A. Herskovic, L. Leichman, J. S. Brindle, V. K. Vaitkevicius, et al., “Progress Report of Combined Chemoradiotherapy versus Radiotherapy Alone in Patients with Esophageal Cancer: An Intergroup Study,” Journal of Clinical Oncology, Vol. 15, No. 1, 1997, pp. 277-284.
[27] N. K. Kim, Y. S. Park, D. S. Heo, C. Suh, S. Y. Kim, K. C. Park, et al., “A Phase III Randomized Study of 5-Fluorouracil and Cisplatin versus 5-Fluorouracil, Doxorubicin, and Mitomycin C versus 5-Fluorouracil Alone in the Treatment of Advanced Gastric Cancer,” Cancer, Vol. 71, No. 12, 1993, pp. 3813-3818. doi:10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5
[28] U. Vanhoefer, P. Rougier, H. Wilke, M. P. Ducreux, A. J. Lacave and E. Van Cutsem, et al., “Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin versus Etoposide, Leucovorin, and Fluorouracil versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group,” Journal of Clinical Oncology, Vol. 18, No. 14, 2000, pp. 2648-2657.
[29] E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, et al., “V325 Study Group. Phase III Study of Docetaxel and Cisplatin plus Fluorouracil Compared with Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group,” Journal of Clinical Oncology, Vol. 24, No. 31, 2006, pp. 4991-4997. doi:10.1200/JCO.2006.06.8429
[30] K. Kondo, M. Murase, Y. Kodera, S. Akiyama, K. Ito, Y. Yokoyama, et al., “Feasibility Study on Protracted Infusional 5-Fluorouracil and Consecutive Low-Dose Cisplatin for Advanced Gastric Cancer,” Oncology, Vol. 53, No. 1, 1996, pp. 64-67. doi:10.1159/000227537
[31] R. Kim, S. Murakami, Y. Ohi, H. Inoue, K. Yoshida and T. Toge, “A Phase II Trial of Low Dose Administration of 5-Fluorouracil and Cisplatin in Patients with Advanced and Recurrent Gastric Cancer,” International Journal of Oncology, Vol. 15, No. 5, 1999, pp. 921-926.
[32] H. Kusumoto, Y. Maehara, T. Kusumoto, H. Anai, K. Akazawa and K. Sugimachi, “Chemosensitivity Differences between Primary and Metastatic Lesions of Linical Gastric Cancer,” European Journal of Surgical Oncology, Vol. 14, No. 6, 1988, pp. 685-689.
[33] H. Miyamoto, M. Ogawa, J. Inagaki, N. Horikoshi, K. Ezaki, K. Inoue, et al., “Combination Chemotherapy of Advanced Gastric Cancer with Adriamycin, Mitomycin C, and Ftorafur,” Japanese Journal of Cancer and Chemotherapy, Vol. 10, 1983, pp. 1160-1164.
[34] Y. S. Chung, Y. Yamashita, T. Inoue, T. Matsuoka, B. Nakata, N. Onoda, et al., “Continuous Infusion of 5-Fluorouracil and Low Dose Cisplatin Infusion for the Treatment of Advanced and Recurrent Gastric Adenocarcinoma,” Cancer, Vol. 80, 1997, pp. 1-7. doi:10.1002/(SICI)1097-0142(19970701)80:1<1: :AID-CNCR1>3.0.CO;2-#
[35] J. S. Macdonald, P. S. Schein, P. V. Woolley, T. Smythe, W. Ueno, D. Hoth, et al., “5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric Cancer,” Annals of Internal Medicine, Vol. 93, 1980, pp. 533-536.
[36] J. Mitry, P. Taneb, V. Artru, V. Boige, J. N. Vaillant, M. C. Clavero-Fabri, et al., “Combination of Folinic Acid, 5-Fluorouracil Bolus and Infusion, and Cisplatin (LV5FU2-P Regimen) in Patients with Advanced Gastric or Gastroesophageal Junction Carcinoma,” Annals of Oncology, Vol. 15, No. 5, 2004, pp. 765-769. doi:10.1093/annonc/mdh182
[37] M. Ychou, C. Astre, P. Rouanet, J. M. Fabre, B. SaintAubert, J. Domergue, et al., “A Phase II Study of 5-Fluorouracil, Leucovorin and Cisplatin (FLP) for Metastatic Gastric Cancer,” European Journal of Cancer, Vol. 32A, No. 11, 1996, pp. 1933-1937. doi:10.1016/0959-8049(96)00147-5
[38] C. Louvet, F. Carrat, F. Mal, M. Mabro, K. Beerblock, J. C. Vaillant, et al., “Prognostic Factor Analysis in Advanced Gastric Cancer Patients Treated with Hydroxyurea, Leucovorin, 5-Fluorouracil, and Cisplatin (HLFP Regimen),” Cancer Investigation, Vol. 21, No. 1, 2003, pp. 14-20. doi:10.1081/CNV-120016399
[39] J. Lee, T. Lim, J. E. Uhm, K. W. Park, S. H. Park, S. C Lee, et al., “Prognostic model to Predict Survival Following First-Line Chemotherapy in Patients with Metastatic Gastric Adenocarcinoma,” Annals of Oncology, Vol. 18, No. 5, 2007, pp. 886-891. doi:10.1093/annonc/mdl501
[40] I. Chau, A. R. Norman, D. Cunningham, J. S. Waters, J. Oates and P. J. Ross, “Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic EsophagoGastric Cancer—Pooled Analysis from Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data,” Journal of Clinical Oncology, Vol. 22, 2004, pp. 2395-2403. doi:10.1200/JCO.2004.08.154

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.